Pharmaceuticals, Biotechnology & Life Sciences

Moderna’s legal chief buys shares after a $2.25B patent settlement, showing insider confidence and a clearer IP roadmap for investors.

Teva insider trades signal confidence in its new biologics pipeline and strategic shift from generics—an investor‑friendly, risk‑managed endorsement of future growth.

Alnylam insider trades are routine tax‑cover moves, yet they coincide with strategic moves into cardiovascular RNAi therapies and robust partnership plans, underscoring a bullish pipeline and confident market‑access strategy.

Insider buying spurs optimism at Klotho Neurosciences, as executives acquire millions of shares amid the company’s pivot from biotech to critical‑minerals mining, potentially unlocking new growth and shareholder value.

Insightful look at PepGen Inc.’s insider trades reveals how biotech executives balance tax, liquidity, and long‑term value amid shifting reimbursement and tech trends.

Vertex’s insider sales reveal routine portfolio management, not distress – still a strong CF, oncology and pain pipeline poised for growth.

Insider buying signals Klotho’s pivot to critical‑mineral mining—CEO’s 350k share grant shows confidence, hinting at new revenue streams and upside potential for investors.

Insider buys 350k Klotho shares as company pivots from neuro‑therapeutics to mining assets, boosting investor confidence in its new growth strategy.

Discover how CFO insider trades reveal confidence in Emergent BioSolutions’ biotech pipeline and market strategy.

Erasca’s insider buying signals confidence in its ERAS‑4001 KRAS‑targeted drug and IP gains—insightful for investors watching biotech volatility.